



Sapientia  
pharmaceuticals

**Applying Wisdom to Drug Discovery and Development**

# ABOUT SAPIENTIA PHARMACEUTICALS

**Founded in 2014, Sapienia Pharmaceuticals is an oncology focused biotechnology company that develops therapies for multiple cancer indication. Sapienia's core competencies include oncology, drug discovery, drug development, clinical pharmacology, molecular biology, immunology, immunotherapy, and targeted cancer immunotherapies.**

**The Company is based in Havertown PA, and currently has a strong scientific team, an excellent intellectual property portfolio, and an experienced advisory board.**

# HIGHLIGHTS

## Wholly-owned Subsidiary of BriaCell

- BriaCell Therapeutics Corp. acquired Sapientia in 2017. Sapientia is BriaCell's drug discovery and development arm.

## Innovative high- quality drug candidates

- Developing the first off-the-shelf personalized immunotherapy for advanced breast cancer
- Activity against “undruggable” RAS transformed tumors (30% of all cancers) with a novel mechanism and excellent intellectual property protection

## Attractive asset portfolio

- Wholly-owned drug discovery programs contributes to a robust drug candidate pipeline, offering an attractive asset portfolio

## Focus on areas of significant unmet need

- Streamlined regulatory processes that may allow speedy progression of drug candidates in clinical trials and market exclusivity

## Experienced management team

- Over 50 years of combined drug discovery and development experience
- History of successfully advancing pipeline candidates to significant value inflection points

# KEY SCIENTIFIC PERSONNEL

## William V Williams, MD CEO, Founder

Dr. Williams served as head of rheumatology research at University of Pennsylvania. At GlaxoSmithKline he was Head of Experimental Medicine and VP of Clinical Pharmacology. As VP of Exploratory Development at Incyte he brought over a dozen compounds into the clinic and established proof-of-concept for compounds in multiple disease areas including oncology, rheumatoid arthritis, psoriasis and diabetes. He has been responsible for several successful New Drug Applications, including Jakafi for myelofibrosis and polycythemia vera, Bexxar for lymphoma and Boniva for osteoporosis. He has over 120 peer reviewed publications and over 20 patents.

## Markus Lacher, PhD CSO

In addition to his role as CSO at Sapientia, Dr. Lacher is currently the Senior Director R&D at BriaCell Therapeutics, Sapientia's parent company. Dr. Lacher has been in charge of cGMP manufacturing of SV-BR-1-GM and has participated in the discovery of the mechanism of action of SV-BR-1-GM. His career included the founding of T cell Therapeutics, a biotechnology company that was dedicated to developing and commercializing immunotherapies for the selective ablation of cancer cells resistant to standard treatments. He served as the CEO of this company. In addition, Dr. Lacher worked as a Scientist at CESCA Therapeutics, Inc., OncoCyte Corporation and BioTime, Inc.

## Vivek Sunkari, PhD Sr. Scientist

Dr. Sunkari has over 10 years of biotech, pharma and academic research experience. He has served as the Immunology Discovery Scientist of Lake Pharma Inc. He was a postdoctoral researcher at the Stanford School of Medicine, where he studied the role of extracellular matrix in inflammatory diseases. Before that, Dr. Sunkari did his graduate work at the Karolinska Institute, Sweden, and identified several pathways involved in chronic tissue repair and regeneration. Dr. Sunkari was also a co-founder of LymeTek Inc., which focuses on identifying antibiotics that can influence immune and inflammatory systems to treat Lyme disease.

## KEY SCIENTIFIC PERSONNEL

### Charles Wiseman, MD CMO

Dr. Charles Wiseman, CMO - Dr. Wiseman has 45 years of experience and is considered a pioneer of targeted immunotherapies. In the past, he has served as Director of the Immunotherapy Lab, St. Vincent Medical Center; Chief of the Breast Cancer Basic Research Lab, Univ. of Texas MD Anderson Hospital & Tumour Institute; Assist. Prof., Dept of Molecular Carcinogenesis & Virology, MD Anderson; and acting Chief, Div. of Oncology, White Memorial Medical Center, Los Angeles. He is currently a Managing member, Founder, Director, and former CEO of BriaCell Biologics, LLC; Principal of Wiseman Research Initiatives, LLC; and President of Wiseman Cancer Research Foundation, a 501c3 public charity. Dr. Wiseman has played a key role in the development of SV-BR-1-GM, both through the work performed at St. Vincent Medical Center and through his role at BriaCell.

## KEY BUSINESS PERSONNEL

### Mr. Martin Schmiege CFO

Mr. Schmiege has over 35 years of biotech, med-tech, and pharma experience. He has served as the CFO of Sirna Therapeutics Inc and Isologen Inc. He has also served as the CEO of Freedom-2 Inc, now known as PharmaCyte Inc. In addition, he has been an advisor to a number of companies in the industry, including Caladrius Biosciences, Inc., Beckman Coulter Genomics, Calimmune, Inc., Cryoport, Inc., Vetbiologics, a division of U.S. Stem Cell, Inc., Sapientia Pharmaceuticals, Inc., and Rokk3r Labs, LLC.

# ACCOMPLISHED SCIENTIFIC ADVISORY BOARD

**Brian Metcalf, Ph.D.**

- Recently retired as CSO from Global Blood Therapeutics
- Former Head of Research & Development, Incyte Corporation
- Former Head of Medicinal Chemistry, SmithKline Beecham

**Douglas Faller, M.D.,  
Ph.D.**

- Professor of Medicine, Pediatrics, Biochemistry, Microbiology, Pathology and Laboratory Medicine; Hematologist/Oncologist; former Director of the Cancer Center; Boston University School of Medicine.
- Founder of several successful biotechnology companies

**Robert Williams, Ph.D.**

- University Distinguished Professor of Chemistry, Colorado State University
- Founder of several successful biotechnology companies including Microcide, Xcyte Therapies, HemaQuest, Arch Therapeutics and Cetya Therapeutics

**Thomas Kieber-  
Emmons, Ph.D.**

- Deputy Director, University of Arkansas Cancer Center
- Expert in targeted cancer immunotherapies, structural biology and computational chemistry

**Maria Trojanowska,  
Ph.D.**

- Professor of Medicine, Boston University School of Medicine
- Director, The Arthritis Center